CervoMed Inc.
$ 4.52
82.26%
16 Jun - close price
- Market Cap 22,961,600 USD
- Current Price $ 4.52
- High / Low $ 7.45 / 2.99
- Stock P/E N/A
- Book Value 1.15
- EPS -3.28
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.72 %
- ROE -1.33 %
- 52 Week High 11.25
- 52 Week Low 2.13
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$19.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-18 | 2026-03-13 | 2025-11-07 | 2025-08-08 | 2025-05-12 | 2025-03-17 | 2024-11-12 | 2024-08-09 | 2024-05-14 | 2024-03-25 | 2023-11-13 | 2023-08-08 |
| Reported EPS | -0.86 | -0.88 | -0.84 | -0.7 | -0.56 | -0.8 | -0.5462 | -0.27 | -0.41 | -0.38 | -0.7 | -1.5537 |
| Estimated EPS | -0.7929 | -0.7017 | -0.46 | -0.68 | -0.6233 | -0.6343 | -0.41 | -0.31 | -0.39 | -0.29 | -0.95 | -2.9 |
| Surprise | -0.0671 | -0.1783 | -0.38 | -0.02 | 0.0633 | -0.1657 | -0.1362 | 0.04 | -0.02 | -0.09 | 0.25 | 1.3463 |
| Surprise Percentage | -8.4626% | -25.4097% | -82.6087% | -2.9412% | 10.1556% | -26.1233% | -33.2195% | 12.9032% | -5.1282% | -31.0345% | 26.3158% | 46.4241% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRVO
2026-06-16 16:11:09
This article mentions CervoMed (CRVO.US) in the context of a discussion on the moomoo Community platform. The content is primarily disclaimers and navigation elements for the moomoo platform, indicating that CervoMed was a topic of discussion among users.
2026-06-16 14:11:10
CervoMed Inc. (DUS:DP8) reported its cash flow details, indicating a free cash flow of €-6.94 million for Q1 2026. For the full year 2025, the company recorded a free cash flow and operating cash flow of €-19.97 million each. The article provides a historical overview of the company's operating, investing, and financing activities.
2026-06-16 14:11:09
The article focuses on the current ratio of CervoMed Inc., traded on the Dusseldorf Stock Exchange under the symbol DP8. It provides a brief financial overview within the TradingView platform, noting that market data is from ICE Data Services and reference data from FactSet. The core content is very minimal, presenting only the company name and stock ticker in a web page context.
2026-06-16 14:09:49
This article provides details on the cash generated from the financing activities of CervoMed Inc., traded on the Dusseldorf Stock Exchange under the symbol DP8. It presents an overview of the company's financial data, though specific figures for cash from financing activities are not explicitly stated in the provided text. The content indicates the availability of market and reference data, with all rights reserved by respective providers.
2026-06-16 14:09:49
CervoMed Inc. (CRVO) stock surged over 22% after securing a $10.5 million private placement, extending its cash runway into Q2 2027 and enabling the pursuit of a strategic partner for Phase 3 neflamapimod trials for dementia with Lewy bodies. A major insider, Joshua S. Boger, also purchased 955,414 shares worth $3 million. While dilution is a factor, the financing reduces near-term survival risk, making CRVO a high-beta catalyst play for traders.
2026-06-16 14:09:49
CervoMed Inc. (CRVO) shares surged over 30% in premarket trading following an SEC filing that revealed a trust linked to a company director purchased approximately $3 million in units. This insider-related transaction, priced above Monday's close, comes on the heels of a $10.5 million private placement and signals confidence, although dilution risks remain. Investors are now focused on the company securing a strategic partner for its neflamapimod Phase 3 dementia with Lewy bodies program, considered the next major catalyst.
